Efficacy of secukinumab in treating psoriasis
The interleukin-17A (IL-17A) inhibitor secukinumab shows promise as a treatment option for patients with moderate to severe psoriasis

To continue enjoying this article, please sign in. You can register for free for limited further access, or subscribe now for full access to all our content. View our subscription and registration options.